Wuxi Biologics has confirmed its intention to go public in an IPO application that reveals the contracter has seen revenue double and profits increase three-fold since 2014.
Zhejiang Medicine Co. Ltd. Health Canada Inspection List
Zhejiang Medicine Co. Ltd. Receives FDA Warning Letter
Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) announced today that they initiated First-In-Human phase I clinical trial with ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate (ADC) targeting Her2. Ambrx ARX788 may hold the potential for a broader patient population than the currently available Her2 targeting therapies. The multicenter study will be conducted at several sites within Australia and New Zealand. The primary end point is safety and tolerability, and the pharmacokinetics of ARX788 will also be evaluated. The application for the initiation of clinical trial in China was submitted to the China FDA early this year.